瘦组织与脂肪组织的比率作为认知障碍的风险因素在接受维护血液透析的患者中
Maolu Tian1, Jing Yuan2, Pinghong He3
1School of Medicine, Guizhou University, Guiyang, China; Renal Division, Department of Medicine, Guizhou Provincial People's Hospital, Guiyang, China; NHC Key Laboratory of Pulmonary Immunological Disease, Guizhou Provincial People's Hospital, China.
Journal of psychosomatic research
|September 27, 2023
概括
瘦与脂肪组织比率,而不是BMI,是维持血液透析患者认知障碍的重要预测指标. 较低的比率表明患有认知衰退的风险更高.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 老年学是指老年学的学科.
- 代谢健康 代谢健康
背景情况:
- 认知障碍 (CI) 是接受维护血液透析 (MHD) 的患者常见的并发症.
- 在MHD患者中,身体质量指数 (BMI) 和CI之间的关系受到争论.
- 身体成分,特别是瘦与脂肪 (L/F) 组织比率对MHD患者的CI风险的影响以前没有被研究过.
研究的目的:
- 调查L/F组织比率与MHD患者发生IC的风险之间的关联.
- 确定L/F组织比是否是该人群中CI的独立风险因素.
主要方法:
- 一项观察性队列研究涉及3356名MHD患者,随访时间平均为2年.
- 身体组成,包括瘦组织质量 (LTM) 和脂肪组织质量 (FTM),使用生物阻抗光谱法 (BCM-BIS) 进行评估.
- 计算了L/F组织比率,并使用考克斯回归分析来确定事件CI的危险比率 (HRs),通过迷你精神状态检查得分来衡量.
主要成果:
- 在随访期间,超过37%的患者出现了事件CI.
- 较低的L/F组织比率与较高的CI风险显著相关 (HR 1.51).
- 这种关联在各种子组中保持一致,包括老年人和受教育程度较低的参与者,BMI没有发现与CI独立相关.
结论:
- L/F组织比是MHD患者发生认知障碍的独立风险因素.
- 与BMI不同,L/F组织比率提供了关于这个患者群体认知衰退的有价值的预测信息.
相关概念视频
01:17Factors Affecting Renal Clearance: Renal Impairment
114
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
114
01:25Hemodialysis III: Nursing Management
31
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
31
01:28Chronic Kidney Disease III: Interprofessional Care
28
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
28
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:24Chronic Kidney Disease II: Clinical Manifestations
16
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
16
01:11Renal Failure: Dose Adjustments
109
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
109